SCHEMBL6442641

SCHEMBL6442641

CCOC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](OCC)C=C[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
NR1I2 O75469 1/20 0.39
NR3C1 P04150 1/20 0.39
CYP17A1 P05093 1/20 0.39
PGR P06401 1/20 0.39
AR P10275 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
OPRK1 P41145 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP19A1 P11511 4/20 0.37
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441605 1.00 CYP3A4 (0.39) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6438410 0.95 CYP3A4 (0.40) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6444181 0.93 MEN1 (0.38) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6443061 0.93 MEN1 (0.38) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6443299 0.93 CYP3A4 (0.41) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6442035 0.93 CYP3A4 (0.41) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6441540 0.92 CYP3A4 (0.39) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6448565 0.92 CYP3A4 (0.39) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6444030 0.92 LMNA (0.38) CYP3A4LMNAMAPTNR1I2NR3C1
SCHEMBL6443327 0.92 LMNA (0.38) CYP3A4LMNAMAPTNR1I2NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050159366-A1 Pharmaceutical compositions and treatment methods - 8 BIOVIE INC. 2005-07-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159366-A1 Pharmaceutical compositions and treatment methods - 8 HSD17B7, NR5A1, HSD3B1 CYP3A4 144/4885LMNA 4071/4885MAPT 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.